The Cost of Trading Transparency: What We Know, What We Don't Know, and How We Will Know

被引：2
|
作者：
Gastineau, Gary L. [1 ]
机构：
[1] ETF Consultants LLC, Summit, NJ USA
来源：
JOURNAL OF PORTFOLIO MANAGEMENT | 2008年 / 35卷 / 01期
关键词：
D O I：
10.3905/JPM.2008.35.1.72
中图分类号：
F8 [财政、金融];
学科分类号：
0202 ;
摘要：
Results from several major studies of index composition changes indicate that trading transparency accounts for more than half the market impact cost of composition changes in the two most popular U. S. indices. The growth of transparent custom index exchange-traded funds (ETFs) and the introduction of actively managed ETFs with relatively transparent trading will increase investor exposure to trading transparency costs. Fortunately, researchers can quantify the performance penalty that trading transparency imposes on investors.
引用
收藏
页码：72 / +
页数：11
相关论文
共 50 条
  • [41] Commentary: When we don't know what we don't know
    Paone, Gaetano
    [J]. JTCVS TECHNIQUES, 2021, 6 : 102 - 103
  • [42] HOW DO WE KNOW WHAT WE KNOW AND HOW CAN WE EXTEND WHAT WE KNOW
    ROSENBLOOM, DH
    [J]. PUBLIC ADMINISTRATION REVIEW, 1991, 51 (02) : 95 - 96
  • [43] INSIDER TRADING - WHAT WE KNOW AND WHAT WE DONT KNOW
    ROZEFF, MS
    [J]. ETHICS OF ORGANIZATIONAL TRANSFORMATION: MERGERS, TAKEOVERS AND CORPORATE RESTRUCTURING, 1989, : 221 - 233
  • [44] Treatment of colonic diverticulitis - What we know and what we don't know
    Youssef, P
    Hoene, A
    Paul, H
    [J]. ZENTRALBLATT FUR CHIRURGIE, 1998, 123 : 23 - 26
  • [45] Understanding and treating trichotillomania: What we know and what we don't know
    Woods, Douglas W.
    Flessner, Christopher
    Franklin, Martin E.
    Wetterneck, Chad T.
    Walther, Michael R.
    Anderson, Emily R.
    Cardona, Dodamd
    [J]. PSYCHIATRIC CLINICS OF NORTH AMERICA, 2006, 29 (02) : 487 - +
  • [46] Human Extraintestinal Sarcocystosis: What We Know, and What We don’t Know
    V. C. Harris
    M. van Vugt
    E. Aronica
    G. J. de Bree
    C. Stijnis
    A. Goorhuis
    M. P. Grobusch
    [J]. Current Infectious Disease Reports, 2015, 17
  • [47] STEROID SAFETY: WHAT WE KNOW, WHAT WE DON'T KNOW AND WHY
    Dixon, Will G.
    [J]. RHEUMATOLOGY, 2015, 54 : 16 - 16
  • [48] The Drosophila circadian clock:: what we know and what we don't know
    Blau, J
    [J]. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2001, 12 (04) : 287 - 293
  • [49] A TRANSLATIONAL VIEW ON NARCOLEPSY: WHAT WE KNOW, AND WHAT WE DON'T KNOW
    Baumann, C. R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 14 - 14
  • [50] Human Extraintestinal Sarcocystosis: What We Know, and What We don't Know
    Harris, V. C.
    van Vugt, M.
    Aronica, E.
    de Bree, G. J.
    Stijnis, C.
    Goorhuis, A.
    Grobusch, M. P.
    [J]. CURRENT INFECTIOUS DISEASE REPORTS, 2015, 17 (08)
12345